ACTG publishes LATITUDE findings in New England Journal of Medicine

ACTG announced that the LATITUDE (A5359) phase 3 study of long-acting cabotegravir plus rilpivirine was published in the New England Journal of Medicine and reported superiority in preventing regimen failure among people with HIV who have adherence challenges with daily oral ART.

ACTG announced publication of the LATITUDE study findings in the New England Journal of Medicine. The NEJM article is titled "Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges." It reports that a long-acting injectable combination of cabotegravir and rilpivirine was superior in preventing regimen failure among people living with HIV who have struggled with daily oral antiretroviral therapy. LATITUDE, also called A5359, is a phase 3 efficacy trial focused on people with adherence challenges. Key details: - The NEJM publication reports results from the LATITUDE (A5359) phase 3 study. - The article reports that long-acting injectable cabotegravir plus rilpivirine was superior in preventing regimen failure among people with adherence challenges to daily oral ART. - LATITUDE is the first randomized study to test this approach in people who have difficulty maintaining oral ART. - Cabotegravir and rilpivirine are approved in the U.S. to be used as injections every one or two months for people with a consistent history of viral suppression. - The announcement notes that an estimated 67% of people living with HIV in the U.S. who take oral ART maintain viral suppression, a context for why the study focused on adherence challenges. Summary: The NEJM publication presents phase 3 evidence that the long-acting injectable combination showed superiority in preventing regimen failure among people with adherence challenges. Undetermined at this time.